Date: 2014-04-07
Type of information: Company acquisition
Acquired company: IQuum (USA)
Acquiring company: Roche (Switzerland)
Amount: up to $ 450 million (€324 million)
Terms: * On April 7, 2014, Roche has announced the acquisition of IQuum, Inc. (IQuum) based in Marlborough, Massachusetts, USA. IQuum is a privately held company focused on developing point of care offerings for the molecular diagnostics market. Under the terms of the agreement, Roche will pay IQuum shareholders $ 275 million upfront and up to $ 175 million in contingent product related milestones. The transaction is subject to customary closing conditions. Once the transaction is complete, IQuum will be integrated into Roche Molecular Diagnostics.
Details: The acquisition will provide Roche with access to IQuum’s Laboratory-in-a-tube (Liat™) System, which enables healthcare workers to perform rapid molecular diagnostic testing in a point of care setting, closer to patients and with minimal training. The Liat™ Analyzer and Liat™ Influenza A/B Assay, the first test available for use on the system, produce reliable and accurate lab-like results and are CE marked and FDA cleared.
Related: molecular diagnostic point of care diagnostic
